On September 22, Celldex Therapeutics reported topline results from two Phase 3 trials of barzolvolimab in chronic spontaneous urticaria, and by mid-morning its shares were down about 13 percent. The efficacy numbers explain why analysts called the dataset the best the field has seen. The safety slide explains the other half of the trading day. Both halves are in the same document, and the way the market weighed them is the most useful thing to understand about what happens next.
The two trials delivered what they were designed to deliver
Barzolvolimab is a humanized antibody that binds KIT, the receptor mast cells depend on to survive. Chronic spontaneous urticaria is, in the simplest terms, a mast cell disease: the cells release histamine and other mediators into skin without an external trigger, producing hives, deep swelling and an itch that interrupts sleep and work. Every approved therapy for the condition blocks a mediator or a receptor. This one removes the cell that produces them.
The company's results release states that the two trials, EMBARQ-CSU1 and EMBARQ-CSU2, randomized 1,939 patients who remained symptomatic on H1 antihistamines, including patients whose disease had already failed omalizumab. Both met the primary endpoint, the mean change from baseline in the weekly urticaria activity score at week 12. Placebo arms improved by 10.7 and 11.4 points. The active arms improved by 20.2 and 20.5 points in the first trial and by 20.2 and 19.7 in the second, each at p less than .00001. All key secondary endpoints were met, and the effect was sustained or deeper at week 24.
The secondary numbers carry more meaning for patients than the primary one does. A complete response means no itch and no hives at all. Between 42 and 46 percent of treated patients reached that at week 12, against 9.3 and 12.6 percent on placebo. By week 24 the treated rates were 45 to 54 percent, against roughly 15 to 18 percent on placebo. Among patients who started the trial with angioedema, the deep swelling that sends people to emergency departments, complete resolution ran 62.7 to 74.3 percent against about 34 percent on placebo.
Those are large effects by the standards of this disease, and the program is described as the largest ever conducted in antihistamine-refractory CSU.
Two design details matter for what a label would eventually authorize. The first regimen is 150 milligrams every four weeks after a loading dose, matching the dosing rhythm patients already know from omalizumab. The second is 300 milligrams every eight weeks after a larger loading dose, which would cut the number of clinic visits and injections in half for a disease that requires years of continuous treatment. Both dose regimens performed about the same on the primary endpoint, which is the outcome a company wants when it is trying to offer physicians a choice of schedules rather than a single one.
The placebo response is also worth reading carefully, because it shapes how the trial should be judged. Placebo arms improved by roughly 11 points on a scale where baseline scores were about 30, which is a large move for an inactive treatment and consistent with what CSU trials have shown for years: symptoms fluctuate, patients enrolled in a study tend to improve, and expectation does measurable work in a disease whose main symptom is perceived. The active arms still separated from that by another ten points, and separation of that size on top of a substantial placebo response is the reason the efficacy claims are not in dispute.
The omalizumab-refractory group is where the unmet need lives
Omalizumab has been the biologic standard since 2014. It works well for many patients and not at all for a substantial minority, and roughly 60 percent of people treated for CSU are not fully controlled on standard-dose antihistamines. Payers commonly anchor step therapy to omalizumab, so a drug that performs after omalizumab has failed is addressing the population with the fewest options left.
That is the subpopulation Celldex designed the trials to measure, and it hit there too. Complete response at week 12 among omalizumab-refractory patients ran 41.7 to 55.3 percent against 9.3 and 15.1 percent on placebo. No validated biomarker yet tells a physician which of the approved agents to choose, so evidence in the population that has already failed the first biologic is the evidence that changes a treatment algorithm.
The company's positioning is explicit. Chief Executive Anthony Marucci described the results as "best-in-disease in CSU" and said the drug is aimed at two places at once: first-line therapy for patients with severe disease or angioedema, and the second-line advanced therapy after omalizumab.
Barzolvolimab would arrive into a market that changed while it was in development. Omalizumab held the field alone for a decade, then dupilumab was approved for the indication in 2025 and remibrutinib, an oral BTK inhibitor taken twice daily, followed later that year. All three work by interrupting a signal. None removes the cell that generates the signals, and none has produced complete response rates in the range these two trials reported. That is the commercial argument, and it survives the safety discussion mostly intact: a patient who has cycled through an antihistamine, an injected biologic and an oral inhibitor without reaching zero symptoms is a patient whose physician will read a safety profile differently than a first-line prescriber would.
Two cases on the slide, and one more that investors skipped
The adverse-event slide is the reason the shares fell. Two Grade 4 anaphylaxis events, meaning life-threatening, occurred in one of the barzolvolimab-dosed groups and were assessed as probably related to the drug. One patient was hospitalized and the other was treated and discharged. A third case occurred after a dose of placebo, a detail that appeared in the same slide and received less attention.
Marucci told analysts on the results call that the incidence was low across the roughly 2,400 patients treated in the program so far, a characterization the company repeated in its release. Celldex's release describes the drug as well tolerated with a favorable safety profile through the 24-week placebo-controlled period, consistent with earlier studies. The overall discontinuation rate was 16 percent, with changes in hair color and skin pigmentation among the events leading to it. Neutropenia has been a persistent question for this mechanism, and the most common side effects beyond that are cosmetic.
Both descriptions can be accurate at once. An event rate in the low tenths of a percent is small in a program of this size and enormous in a disease that does not shorten life, which is the trade the FDA will be asked to make.
Why this signal lands harder than the same signal in oncology
Risk tolerance tracks the severity of the disease being treated. Chronic spontaneous urticaria affects about 0.78 percent of American adults, and its burden is measured in lost sleep, lost work, emergency visits for swelling and a quality of life that patients consistently rate below that of people with far more dangerous conditions. It is not fatal. A drug that carries a life-threatening hypersensitivity risk is judged differently when the alternative is itch than when the alternative is death.
Class precedent cuts both ways. Omalizumab carries a boxed warning for anaphylaxis at a rate in the low tenths of a percent, and it became the standard of care. Dupilumab, approved for CSU in 2025, carries hypersensitivity warnings. The oral BTK inhibitor remibrutinib, approved in late 2025, offers a different risk profile entirely.
Analysts split along exactly that line. Kristen Kluska of Cantor Fitzgerald wrote that the efficacy looks like "the best Phase 3 data set we've seen" and that the safety profile appears favorable relative to other biologics generating billions in revenue. She also suggested physicians may simply administer the first dose in a clinic under observation, which is how omalizumab's risk was managed for years before home dosing became common. Alex Thompson of Stifel took a similar view, noting that some of the largest-selling biologics carry anaphylaxis warnings and that he still expects meaningful sales even if the label includes a boxed warning and the drug is placed last in the sequence.
What the 52-week data can still change
Three things about the anaphylaxis cases are not yet public and each one matters. Whether the events followed first exposure or later doses determines whether clinic observation solves the problem or only appears to. Whether they were associated with a particular dose level matters for the two regimens under study, and coverage of the call pointed to the lower-dose group. And whether the events recurred in the patients who continued treatment matters for the long-term extension study now enrolling.
The trials continue to 52 weeks, and the company plans to present the full dataset at a medical meeting before filing a Biologics License Application in 2027. Analysts have put peak sales near $4.8 billion on the strength of the efficacy. That number assumes an approved label that permits broad use, which is the assumption the safety data will test.
There is also a strategic fact worth holding alongside the trial results. Celldex spent years as an oncology company with a series of failures, and barzolvolimab is the asset the company rebuilt itself around. In July it discontinued development of the drug in prurigo nodularis after a mid-stage failure, a reminder that depleting mast cells is not therapeutic progress in every disease where the cells are involved.
What the next year decides
For a patient with severe urticaria who has failed antihistamines and omalizumab, the trial results are the most encouraging news the field has produced, and they arrive with a safety question the company will have to answer in front of regulators rather than in a press release. For Celldex, the path runs through a 52-week dataset, a medical meeting, and a filing in 2027 where the debate will not be about whether the drug works. It will be about how the label describes who should receive it, what monitoring it requires, and where it sits relative to three approved alternatives.
That is a strange place for a company to be after two positive Phase 3 trials. It is also a familiar one in immunology, where the drugs that endure are rarely the ones with the cleanest efficacy curves but the ones whose risks physicians learn to manage. The next twelve months will determine whether two life-threatening events become a monitoring protocol or a limitation that keeps a drug behind the ones it beat on the endpoints.
Primary sources
- Celldex Therapeutics, Exhibit 99.1 to Form 8-K, Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints (September 22, 2026).
- BioPharma Dive, Celldex sinks as safety concerns cloud immune drug results (September 22, 2026).
- ClinicalTrials.gov, NCT06445023 (EMBARQ-CSU1) and NCT06455202 (EMBARQ-CSU2).
- Dermatology Advisor, Chronic Spontaneous Urticaria in 2026: Update on Anti-IgE Treatment, for the approved treatment sequence and the absence of a validated biomarker to guide selection.